Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Toll-like receptor (TLR) agonists improve vaccine immunogenicity and efficacy, but they are currently unlicensed as adjuvants in influenza vaccines. This study aimed to investigate whether a combination of monophosphoryl lipid A (MPL, a TLR4 agonist) and polyriboinosinic polyribocytidylic acid (poly I:C, a TLR3 agonist) can enhance the protective efficacy of an inactivated A/Puerto Rico/8/1934 (A/PR8) H1N1 influenza vaccine against homologous influenza infection and minimize illness outcomes. Results showed that combination MPL and poly I:C adjuvanted influenza vaccination increased the production of antigen-specific antibodies, decreased the levels of cytokines and cellular infiltrates at the infection sites, and induced significant memory T and B cell responses in mice. The results of this study suggest that the combination of MPL and poly I:C can be developed into a possible adjuvant for enhancing the efficacy of influenza vaccines.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382554 | PMC |
| http://dx.doi.org/10.1038/s41598-023-39210-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An NLRP3-stimulatory adjuvant improves the immunogenicity of influenza virus vaccines in mice and non-human primates.
mBio
September 2025
Corner Therapeutics, Watertown, Massachusetts, USA.
Unlabelled: Dendritic cells (DCs) are the primary inducers of immunity induced by infection or vaccination. To stimulate durable T cell-mediated immunity, multiple DC activities are required. DCs must present antigen, express costimulatory molecules, and secrete inflammatory cytokines to direct T cell activation.
View Article and Find Full Text PDFInforming future seasonal influenza and COVID-19 vaccination campaigns based on past experience: a mixed-method approach with eligible populations and healthcare professionals.
Front Public Health
September 2025
Directorate-General of Health (DGS), Lisbon, Portugal.
Background: Seasonal vaccination campaigns against influenza and COVID-19 are critical for protecting vulnerable populations. Scientific evidence on past campaigns is essential for the effectiveness of future campaigns. This study aims to: (1) assess predictors of influenza and COVID-19 vaccination intentions (2) explore perceived barriers and facilitators of 2023-2024 seasonal vaccination campaign.
View Article and Find Full Text PDFH5N1 influenza virus-like particles based on BEVS induce robust functional antibodies and immune responses.
Virology
August 2025
Changchun Institute of Biological Products Co.,Ltd, Changchun, China; State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, China National Biotec Group Company Limited, Beijing, China. Electronic address:
Avian influenza virus infections pose a potential pandemic threat. The currently licensed vaccines have inherent limitations, emphasizing the urgent need for improved influenza vaccines. Here, we developed a novel hemagglutinin (HA) virus-like particle (VLP) vaccine candidate through the baculovirus expression vector system (BEVS).
View Article and Find Full Text PDFCost-Effectiveness Analysis of a Maternal Vaccination Program Against Respiratory Syncytial Virus in Norway.
Influenza Other Respir Viruses
September 2025
Oslo Economics, Oslo, Norway.
Background: Respiratory syncytial virus (RSV) is recognized as the primary cause of hospitalizations among children with lower respiratory tract infections in developed countries, placing a significant burden on both patients and healthcare systems. The efficacy, safety, and immunogenicity of maternal vaccination with the novel RSVpreF vaccine have been evaluated in a Phase III clinical trial, showing a decreased risk of severe infection in infants. Our study assesses the cost-effectiveness of the RSVpreF vaccine and seasonal variation of costs in a Norwegian setting.
View Article and Find Full Text PDFInfluenza vaccination coverage assessments by race and ethnicity can identify populations less protected from influenza morbidity and mortality and help focus vaccination efforts. Across eight Vaccine Safety Datalink health systems, we identified influenza vaccines administered from August 1 through March 31 each season from 2017 to 18 through 2022-23 using electronic health records linked to immunization registries. We calculated crude vaccination coverage for each season among people in five age groups (6 months-8 years, 9-17, 18-49, 50-64, and ≥ 65 years) by self-reported race and ethnicity.
View Article and Find Full Text PDF